• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans

* * * * * 2 votes

Peter Attia interviews Tom Dayspring M.D. and discusses all things lipid in epic 5-part series.

peter attia tom dayspring lipids ldl hdl lpa cholesterol niacin apolipoproteins statins

  • Please log in to reply
1 reply to this topic


  • Member
  • 817 posts
  • 341

Posted 21 October 2018 - 03:44 PM

Almost 8 total hours of interview.







  • Informative x 1
  • like x 1

#2 Andey

  • Guest
  • 598 posts
  • 169
  • Location:Kiev, Ukraine

Posted 26 July 2019 - 07:13 PM

Ive recently listened it for a second time, plus read shownotes for a few particularly interesting topics, its such a gem.

Recent paper on a PSCK9 genotypes helped put it al in the one picture. http://sci-hub.tw/ht...ubmed/31221259 

Looks like low LDL-C is not beneficial from the all cause mortality point of view and thats kinda obvious because low numbers of people with PSCK9 mutation says its a very dangerous one and probably more dangerous in a past, before antibiotics era.

Thats said, Figure 5 in the study shows thats if somebody is in a high risk for CVD, taking statins and PSCK9 inhibitors is the  best thing one could do for all cause mortality. What else could half the all cause mortality risk?

Sadly we dont have much tools for determining CVD risk except for family history and clinical evidence of  advanced disease (CAC score and events history)


  • Informative x 1

To book this BIOSCIENCE ad spot and support Longecity (this will replace the google ad above) - click HERE.

Also tagged with one or more of these keywords: peter attia, tom dayspring, lipids, ldl, hdl, lpa, cholesterol, niacin, apolipoproteins, statins

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users